1 Ligue suisse contre le cancer [Internet]. Berne: le myélome multiple. c2018 [cited 2022 Jun 21]. Disponible sur:
https://www.liguecancer.ch/a-propos-du-cancer/les-differents-types-de-cancer/le-myelome-multiple.
2 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.
3 Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.
4 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
5 Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–9.
6 Faiman B. Diarrhea in Multiple Myeloma: A Review of the Literature. Clin J Oncol Nurs. 2016;20(4):E100–5.
7 Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124(15):2467–8.
8 Nieto JM, Bastidas A. Bile Acid Malabsorption: A Concise Review. Gastroenterol Hepatol Open Access. Epub 2016 Feb 10. doi:10.15406/ghoa.2016.04.00091.
9 Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull. 2009;92:79–93.
10 Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–3.
11 Camilleri M. Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol. 2014;592(14):29670–80.